Drug intelligence / Profile preview

EBNK-001 + interleukin-15 + Keytruda

Development stage: Unknown
Lead developer: Essen Biotech
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

EBNK-001 is an investigational allogeneic natural killer (NK) cell therapy developed by Essen Biotech for the treatment of advanced or metastatic solid tumors. This specific combination regimen involves the administration of EBNK-001 following lymphodepletion with cyclophosphamide and fludarabine, supported by low-dose interleukin-15 (IL-15) to enhance NK cell survival, expansion, and anti-tumor activity. The regimen also includes pembrolizumab (Keytruda), a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. By blocking the PD-1/PD-L1 pathway, pembrolizumab aims to prevent immune evasion and synergize with the NK cells to mount a more robust anti-tumor response. The therapy is currently being evaluated in a Phase 1/2 clinical trial to determine safety, tolerability, and preliminary efficacy in patients with various solid malignancies.

Other names: EBNK-001 + IL-15 + pembrolizumab

Targets

IL15RA (Interleukin-15 receptor subunit alpha)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on EBNK-001 + interleukin-15 + Keytruda.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EBNK-001 + interleukin-15 + Keytruda.

Explore the full profile